CLK2 blockade modulates alternative splicing compromising MYC‐driven breast tumors
Abstract MYC oncogene overexpression/amplification is common in multiple human cancers, in which it regulates proliferation, apoptosis and cell metabolism, among other processes, and its expression associates with poor prognosis. Targeting MYC presents an exciting therapeutic possibility, but develo...
Saved in:
| Main Authors: | Fernando Salvador, Roger R Gomis |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2018-05-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.201809213 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anti‐tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC‐dependent vulnerability
by: Kenichi Iwai, et al.
Published: (2018-05-01) -
Identification and Biological Evaluation of a Novel CLK4 Inhibitor Targeting Alternative Splicing in Pancreatic Cancer Using Structure‐Based Virtual Screening
by: Chun‐Lin Yang, et al.
Published: (2025-05-01) -
Pharmacological CLK inhibition disrupts SR protein function and RNA splicing blocking cell growth and migration in TNBC
by: Nasi Liu, et al.
Published: (2025-07-01) -
RBPMS inhibits bladder cancer metastasis by downregulating MYC pathway through alternative splicing of ANKRD10
by: Jingtian Yu, et al.
Published: (2025-03-01) -
Unveiling alternative splicing dynamics in activated T lymphocytes and their implications for immune checkpoint blockade efficacy
by: Elad Zisman, et al.
Published: (2025-05-01)